Protein inhibitor of activated stat, piasy regulates α-smooth muscle actin expression by interacting with e12 in mesangial cells

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Torikoshi, Kazuo ^a   Abe, Hideharu ^b   Matsubara, Takeshi ^a   Hirano, Takahiro ^b   Ohshima, Takayuki ^c   Murakami, Taichi ^b   Araki, Makoto ^a   Mima, Akira ^a   Iehara, Noriyuki ^a   Fukatsu, Atsushi ^a   Kita, Toru ^d   Arai, Hidenori ^a   Doi, Toshio ^b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^d KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BINDING PROTEIN; E12 PROTEIN; HELIX LOOP HELIX PROTEIN; PROTEIN INHIBITOR OF ACTIVATED STAT; SMALL INTERFERING RNA; SUMO PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GLOMERULONEPHRITIS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; MESANGIUM CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INTERACTION; RNA INTERFERENCE; SUMOYLATION; TRANSCRIPTION REGULATION; TWO HYBRID SYSTEM; UPREGULATION; WESTERN BLOTTING;

ACTINS; ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; COS CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MESANGIAL CELLS; PROTEIN BINDING; PROTEIN INHIBITORS OF ACTIVATED STAT; RATS; RATS, INBRED WKY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION FACTOR 3; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 84864047366     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041186     Document Type: Article

References (40)

1. Mene P, Simonson MS, Dunn MJ, (1989) Physiology of the mesangial cell. Physiol Rev 69: 1347-1424.
2. Schlondorff D, (1987) The glomerular mesangial cell: an expanding role for a specialized pericyte. FASEB J 1: 272-281.
3. Striker LJ, Doi T, Elliot S, Striker GE, (1989) The contribution of glomerular mesangial cells to progressive glomerulosclerosis. Semin Nephrol 9: 318-328.
4. Johnson RJ, Floege J, Yoshimura A, Iida H, Couser WG, et al. (1992) The activated mesangial cell: a glomerular "myofibroblast"? J Am Soc Nephrol 2: S190-197.
5. Alpers CE, Hudkins KL, Gown AM, Johnson RJ, (1992) Enhanced expression of "muscle-specific" actin in glomerulonephritis. Kidney Int 41: 1134-1142.
6. Kumar MS, Hendrix JA, Johnson AD, Owens GK, (2003) Smooth muscle alpha-actin gene requires two E-boxes for proper expression in vivo and is a target of class I basic helix-loop-helix proteins. Circ Res 92: 840-847.
7. Perez-Moreno MA, Locascio A, Rodrigo I, Dhondt G, Portillo F, et al. (2001) A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J Biol Chem 276: 27424-27431.
8. Slattery C, McMorrow T, Ryan MP, (2006) Overexpression of E2A proteins induces epithelial-mesenchymal transition in human renal proximal tubular epithelial cells suggesting a potential role in renal fibrosis. FEBS Lett 580: 4021-4030.
9. Conlon TM, Meyer KB, (2004) Cloning and functional characterisation of avian transcription factor E2A. BMC Immunol 5: 11.
10. Ledent V, Paquet O, Vervoort M, (2002) Phylogenetic analysis of the human basic helix-loop-helix proteins. Genome Biol 3: RESEARCH0030.
11. Massari ME, Murre C, (2000) Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol 20: 429-440.
12. Huggins GS, Chin MT, Sibinga NE, Lee SL, Haber E, et al. (1999) Characterization of the mUBC9-binding sites required for E2A protein degradation. J Biol Chem 274: 28690-28696.
13. Sloan SR, Shen CP, McCarrick-Walmsley R, Kadesch T, (1996) Phosphorylation of E47 as a potential determinant of B-cell-specific activity. Mol Cell Biol 16: 6900-6908.
14. Yamamoto H, Ihara M, Matsuura Y, Kikuchi A, (2003) Sumoylation is involved in beta-catenin-dependent activation of Tcf-4. EMBO J 22: 2047-2059.
15. Dai C, Liu Y, (2004) Hepatocyte growth factor antagonizes the profibrotic action of TGF-beta1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J Am Soc Nephrol 15: 1402-1412.
16. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, et al. (1993) Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 92: 2597-2601.
17. Kawai-Kowase K, Kumar MS, Hoofnagle MH, Yoshida T, Owens GK, (2005) PIAS1 activates the expression of smooth muscle cell differentiation marker genes by interacting with serum response factor and class I basic helix-loop-helix proteins. Mol Cell Biol 25: 8009-8023.
18. Shuai K, (2000) Modulation of STAT signaling by STAT-interacting proteins. Oncogene 19: 2638-2644.
19. Jackson PK, (2001) A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev 15: 3053-3058.
20. Imoto S, Sugiyama K, Muromoto R, Sato N, Yamamoto T, et al. (2003) Regulation of transforming growth factor-beta signaling by protein inhibitor of activated STAT, PIASy through Smad3. J Biol Chem 278: 34253-34258.
21. Nelson V, Davis GE, Maxwell SA, (2001) A putative protein inhibitor of activated STAT (PIASy) interacts with p53 and inhibits p53-mediated transactivation but not apoptosis. Apoptosis 6: 221-234.
22. Sachdev S, Bruhn L, Sieber H, Pichler A, Melchior F, et al. (2001) PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev 15: 3088-3103.
23. Zhou S, Si J, Liu T, DeWille JW, (2008) PIASy represses CCAAT/enhancer-binding protein delta (C/EBPdelta) transcriptional activity by sequestering C/EBPdelta to the nuclear periphery. J Biol Chem 283: 20137-20148.
24. Nishida T, Terashima M, Fukami K, Yamada Y, (2007) Repression of E1AF transcriptional activity by sumoylation and PIASy. Biochem Biophys Res Commun 360: 226-232.
25. Nishida T, Terashima M, Fukami K, (2006) PIASy-mediated repression of the Ets-1 is independent of its sumoylation. Biochem Biophys Res Commun 345: 1536-1546.
26. Kawai-Kowase K, Sato H, Oyama Y, Kanai H, Sato M, et al. (2004) Basic fibroblast growth factor antagonizes transforming growth factor-beta1-induced smooth muscle gene expression through extracellular signal-regulated kinase 1/2 signaling pathway activation. Arterioscler Thromb Vasc Biol 24: 1384-1390.
27. Sinha S, Hoofnagle MH, Kingston PA, McCanna ME, Owens GK, (2004) Transforming growth factor-beta1 signaling contributes to development of smooth muscle cells from embryonic stem cells. Am J Physiol Cell Physiol 287: C1560-1568.
28. Gerhardinger C, Dagher Z, Sebastiani P, Park YS, Lorenzi M, (2009) The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes 58: 1659-1667.
29. Ohshima T, Koga H, Shimotohno K, (2004) Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J Biol Chem 279: 29551-29557.
30. Abe H, Matsubara T, Iehara N, Nagai K, Takahashi T, et al. (2004) Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation. J Biol Chem 279: 14201-14206.
31. Nagai K, Arai H, Yanagita M, Matsubara T, Kanamori H, et al. (2003) Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy. J Biol Chem 278: 18229-18234.
32. Davies M, (1994) The mesangial cell: a tissue culture view. Kidney Int 45: 320-327.
33. Ohshima T, Shimotohno K, (2003) Transforming growth factor-beta-mediated signaling via the p38 MAP kinase pathway activates Smad-dependent transcription through SUMO-1 modification of Smad4. J Biol Chem 278: 50833-50842.
34. Watanabe M, Itoh K, (2011) Characterization of a novel posttranslational modification in neuronal nitric oxide synthase by small ubiquitin-related modifier-1. Biochim Biophys Acta 1814: 900-907.
35. Nishida T, Yasuda H, (2002) PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. J Biol Chem 277: 41311-41317.
36. Nishida T, Terashima M, Fukami K, Yamada Y, (2007) PIASy controls ubiquitination-dependent proteasomal degradation of Ets-1. Biochem J 405: 481-488.
37. Matsubara T, Abe H, Arai H, Nagai K, Mima A, et al. (2006) Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy. Lab Invest 86: 357-368.
38. Sumi E, Iehara N, Akiyama H, Matsubara T, Mima A, et al. (2007) SRY-related HMG box 9 regulates the expression of Col4a2 through transactivating its enhancer element in mesangial cells. Am J Pathol 170: 1854-1864.
39. Ziswiler R, Steinmann-Niggli K, Kappeler A, Daniel C, Marti HP, (1998) Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 9: 2055-2066.
40. Pippin JW, Qu Q, Meijer L, Shankland SJ, (1997) Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. J Clin Invest 100: 2512-2520.